CAS NO: | 154361-50-9 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
500mg | 电议 |
1 g | 电议 |
5 g | 电议 |
10 g | 电议 |
50 g | 电议 |
生物活性 | Capecitabine is an oral prodrug that is converted to its active metabolite, 5-FU, by thymidine phosphorylase. | ||||||||||||||||
IC50& Target | DNA/RNA Synthesis[1] | ||||||||||||||||
体外研究 (In Vitro) | Capecitabine is an anti-cancer chemotherapy drug. It is classified as an antimetabolite. Capecitabine is converted into 5′-deoxy-5-fluorocytidine (5′DFCR), 5′-deoxy-5-fluorouridine (5′DFUR) and 5-FU by carboxylesterases (CES1 and 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP), in both liver and tumour. Capecitabine induces a significant cytotoxic effect in vitro only at high concentrations. Mean IC50values vary from 860 μM in COLO205 cells to 6000 μM in HCT8 cells[2]. | ||||||||||||||||
体内研究 (In Vivo) | A pharmacokinetic/pharmacodynamic study is carried out in mice bearing HCT 116 xenografts receiving 0.52 and 2.1 mmol/kg/d of Capecitabine by oral gavage. Capecitabine administered at 0.52 mmol/kg/day induces partial control of HCT 116 xenografts tumour growth: growth rate =7.5±0.5 on day 21. Capecitabine 2.1 mmol/kg/day achieves complete control of tumor growth during the treatment period: growth rate =1±0.2 on day 21[2]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 359.35 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C15H22FN3O6 | ||||||||||||||||
CAS 号 | 154361-50-9 | ||||||||||||||||
中文名称 | 卡培他滨 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 250 mg/mL(695.70 mM;Need ultrasonic) H2O : ≥ 33.33 mg/mL(92.75 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|